Orla Mining에 대한 매도 수량은 투자자에게 Orla Mining의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Orla Mining (AMEX:ORLA) 주식, 공매도 수량 보고

Orla Mining

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Mexico, and the South Railroad and Lewis gold projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

Orla Mining Ltd

MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.50) by 24 percent. This is a 287.5 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings

Earnings Misses

INKT

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.09 by 711.11 percent. This is a 153.68 percent increase over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $437.822 million which beat the analyst consensus estimate of $424.001 million by 3.26 percent. This is a 14.12 percent decrease over sales of $509.784 million the same period last year.

Earnings Beats

IHS Holding Q4 2024 GAAP EPS $0.73 Beats $0.09 Estimate, Sales $437.822M Beat $424.001M Estimate

<ul>
<li>The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repayment, satisfaction, and discharge or other payment of all or a portion of the Convertible Senior Notes, which may include one or more repurchases pursuant to privately negotiated transactions, and the payment of accrued and unpaid interest thereon, (ii) to pay any fees, costs, and expenses relating to the offering of the Notes and Credit Agreement transactions described below and/or (iii) for general corporate purposes. The Notes offering is subject to market and other conditions, and may not occur as described or at all.</li>
<li>The Company also today announced its intention to amend its existing Credit Agreement to, among other things, extend the maturity of the Company's revolving credit facility from 2028 to 2030 and increase the amount of revolving credit commitments by up to $200 million (resulting in aggregate commitments of up to $500 million). The terms of the commitments and loans under the amended revolving credit facility are expected to be substantially similar to those relating to the commitments and loans under the existing revolving credit facility, except with respect to the aggregate amount of commitments thereunder, the maturity date thereof and certain other terms. The Credit Agreement amendments are subject to market and other conditions, and may not occur as described or at all. The consummation of the Notes offering is not conditioned on the consummation of the Credit Agreement amendments and the consummation of the Credit Agreement amendments are not conditioned on the consummation of the Notes offering</li>
</ul>

Health Care

Financing

General

PODD

Insulet Intends To Offer $450M Principal Amount Of Senior Unsecured Notes Due 2033 In A Private Placement

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

Reiteration

Analyst Ratings

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Guidance

USEA

United Maritime Says Long-term Fundamentals Of Dry Bulk Market Remain Strong

Biotech

PYXS

As Of December 31, 2024, Pyxis Oncology Had Cash And Cash Equivalents Of $128.4M That Is Expected To Provide Cash Runway Into The Second Half Of 2026

Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $16.15 million which beat the analyst consensus estimate of $13.81 million by 16.89 percent.

Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Buy to Neutral and announces $108 price target.

Downgrades

Price Target

PCAR

UBS Downgrades PACCAR to Neutral, Announces $108 Price Target

NCNO

Sandbox Banking's Glyue Introduced In The Zoom App Marketplace

United Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEA#NASDAQ">USEA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.41) by 80.49 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $10.80 million which beat the analyst consensus estimate of $9.50 million by 13.68 percent. This is a 6.90 percent decrease over sales of $11.60 million the same period last year.

United Maritime Q4 2024 Adj EPS $(0.08) Beats $(0.41) Estimate, Sales $10.80M Beat $9.50M Estimate

VRAX

Virax Biolabs Enrolls First Patients In Its UK Based Clinical Study Assessing T Cell Dysfunction In Post-acute Infection Syndromes

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.

STOK

Stoke Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.53) Estimate, Sales $22.60M Beat $4.28M Estimate

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $64 to $66.

RYTM

Needham Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $66

Chinese EV maker&nbsp;XPeng&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading lower premarket on Tuesday. The company reported&nbsp;fiscal&nbsp;fourth-quarter sales growth of&nbsp;23.4%&nbsp;year-on-year to 16.11 billion Chinese Yuan&nbsp;($2.21&nbsp;billion), topping the&nbsp;consensus estimate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44372075/xpeng-reports-fourth-quarter-and-fiscal-year-2024-unaudited-financial-results" rel="noreferrer noopener">of&nbsp;16.02 billion Chinese Yuan</a>.&nbsp;
Total revenues increased 59.4% sequentially in the quarter. The Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival's quarterly vehicle deliveries increased 52.1% Y/Y to 91,507. XPeng's physical sales network had 690 stores, covering 226 cities as of December 31, 2024.
XPeng's self-operated charging station network reached 1,920 stations as of December 31, 2024. Revenues from vehicle sales increased 20.0% Y/Y to 14.67 billion Chinese Yuan ($2.01 billion) on higher deliveries.
Gross margin was 14.4% versus 6.2% a year ago. Vehicle margin was 10.0% versus 4.1% a year ago, primarily attributable to the cost reduction. Operating loss for the quarter was 1.56 billion Chinese Yuan ($0.21 billion). 
Adjusted net loss per ADS of 1.47 Chinese Yuan missed the analyst consensus estimate for a loss of 1.35 Chinese Yuan. In USD terms, the adjusted earnings <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">per ADS was a loss of 20 cents</a> in-line with the consensus of 20 cents loss.
The&nbsp;company held&nbsp;$5.75 billion&nbsp;in cash and equivalents&nbsp;as of December 31, 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/03/44240449/tesla-rival-xpeng-eyes-138-billion-investment-in-humanoid-robots-says-chinese-state-media" rel="noreferrer noopener">Tesla Rival XPeng Eyes $13.8 Billion Investment In Humanoid Robots, Says Chinese State Media</a>
Chairman and CEO of XPENG, Xiaopeng He, highlighted the company&#8217;s strategic positioning to expand its market share in the Smart EV sector both in China and internationally.
He emphasized that AI will play a crucial role in advancing L3 and L4 autonomous driving within the automotive industry. The company&#8217;s goal is to establish XPENG as a globally recognized AI-driven automotive company and a smart technology brand that resonates with users worldwide.
Outlook: XPENG projects first-quarter vehicle deliveries between 91,000 and 93,000, reflecting <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">a surge of 317% to 326.8% Y/Y</a>.
The company anticipates revenue of 15 billion Chinese Yuan to 15.7 billion Chinese Yuan, vs. the consensus of 14.684 billion Chinese Yuan.
Investors can gain exposure to the stock via&nbsp;VanEck Low Carbon Energy ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMOG#NYSE">SMOG</a>) and Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>).
Price Action: XPEV shares are down 0.49% at $24.44 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44267567/xpeng-hesai-group-kohls-groupon-and-tesla-why-these-5-stocks-are-on-investors-radars-today" target="_blank" rel="noreferrer noopener">Xpeng, Hesai Group, Kohl&#8217;s, Groupon, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a></li>
</ul>
Image via Shutterstock.

Large Cap

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

SMOG

TSLA

XPEV

Tesla's China Rival XPeng Delivers Over 91,500 EVs In Q4, Eyes Massive Growth In Q1

UBS analyst Brian Meredith upgrades Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) from Neutral to Buy and raises the price target from $344 to $395.

Upgrades

UBS Upgrades Willis Towers Watson to Buy, Raises Price Target to $395

HC Wainwright &amp; Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and raises the price target from $11 to $12.

BDTX

HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $12

ADTX

Appili Therapeutics Submits Applications For Four New Federal Funding Opportunities

Barclays analyst Lauren Lieberman downgrades PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) from Overweight to Equal-Weight and lowers the price target from $168 to $156.

Barclays Downgrades PepsiCo to Equal-Weight, Lowers Price Target to $156

LASE

Laser Photonics Enhances Gantry Laser Technology In Partnership With Subsidiary Control Micro Systems

Mizuho analyst Maheep Mandloi initiates coverage on Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announces Price Target of $28.

Initiation

Mizuho Initiates Coverage On Bloom Energy with Neutral Rating, Announces Price Target of $28

Small Cap

Press Releases

Orla Mining Announces Strategic Expansion into Canada with Acquisition of the Musselwhite Gold Mine

The Week in Canadian Press Releases: 10 Stories You Need to See

Orla Mining Announces Appointment of New Chief Sustainability Officer

Orla Expands High-Grade Mineralization 800 Metres Beyond Current Resource in Extension Drilling at Camino Rojo, Mexico

Orla Mining Announces Filing of Special Meeting Materials and 43-101 Technical Report for Musselwhite Acquisition

Leading Independent Proxy Advisory Firms Recommend Orla's Shareholders Vote for the Proposed Acquisition of Musselwhite Mine from Newmont Corporation

Orla Mining Achieves Record Annual Gold Production, Meets Improved 2024 Production Guidance, and Announces Preliminary 2025 Guidance

Orla Shareholders Approve Acquisition of Musselwhite Mine

Orla Mining Intersects High Grade Oxide Gold at South Carlin Complex and Advances Permitting for South Railroad Project in Nevada

Comments

Orla Mining

매도 수량

Orla Mining (AMEX:ORLA) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌